Epidarex Capital news and market signals

Glasgow-based biopharmaceutical firm Mironid has closed a, 39.9 million Series B financing round to advance its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease. The capital injection signals continued investor appetite for targeted rare disease therapeutics despite broader market volatility.